Supplementary Figure S1 shows assessment of quality controls when analyzing cfDNA. Supplementary Figure S2 shows a representative electropherogram of assay performance Supplementary Figure S3 shows a the amount of cfDNA in plasma for different risk groups and sample types.
No takes yet. Share an insight, caveat, or question.
Johansson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: